Abstract
The present analyzed study the level, structure and phenotypes of antimicrobial resistance of Streptococcus pyogenes in different regions of Russia and to evaluate their dynamics in period from 1999 to 2003. A total of 103 S. pyogenes from 8 cities and 683 S. pyogenes from 16 cities of Central, North-Western, Southern regions of Russian, Urals and Siberia were included into the phase ‘A’ (1999–2000) and phase «B” (2001–2003) of prospective study PeHAS-I, respectively. Susceptibility to antimicrobials was determined in accordance with National Committee for Clinical Laboratory Standards (NCCLS, USA). Penicillin retained 100% activity against studied population of S. pyogenes (1999–2003). Resistance to macrolides varied from 2% to 12% in 1999–2000 and from 0.15 to 8% in 2001–2003. Proportion of resistance to clindamycin isolates in above specified periods of time was 3% and 1% (р<0,05). Resistance to tetracycline did not change significantly being 47% in 1999–2000 and 45% in 2001–2003. In vitro activity of chloramphenicol also did not change substantially being 88% in 1999–2000 and 86% in 2001–2003. Proportion of multiresistant S. pyogenes was 3.9% in 1999-2000 and 4.0% in 2001–2003. There were no strains resistant to vancomycin, linezolid, levofloxacin and telithromycin found. Thus penicillin, vancomycin, linezolid, levofloxacin and telithromycin were the most active in vitro active against tested isolates. The level of resistance to macrolides and lincosamides was low, thus these antimicrobials can be considered as suitable alternatives to β-lactams. High resistance to tetracycline and chloramphenicol dictates the necessity to limit usage of these antimicrobials for treatment of infections caused by S. pyogenes.
-
1.
Bisno A.L. Acute pharyngitis. N Engl J Med 2001; 344:205-11.
-
2.
Bisno A.L., Stevens D.L. Streptococcal infections of skin and soft tissues. N Engl J Med 1996; 334:240-5.
-
3.
Stevens D.L., Tanner M.H., Winship J., et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 1989; 321:1-7.
-
4.
Felmingham D., Feldman C., Hryniewicz W., et al. Surveillance of resistance in bacteria causing community-acquired respiratory tract infections. Clin Microbiol Infect 2002; 8 Suppl 2:12-42.
-
5.
Schito G.C. Is Antimicrobial resistance also subject to globalization? Clin Microbiol Infect 2002; 8 Suppl 3:1-8.
-
6.
National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically – M100-S13. MIC testing supplemental tables. NCCLS 2004; 48-9.
-
7.
Comité de L’Antibioggramme de la Société Francaise de Microbiologie. Statement 2003. CA-SFM. Zone sizes and MIC breakpoints for non-fastidious organisms. Available at URL: http://www.sfm.asso.fr.
-
8.
Latorre C., Garcia-Rey C., Garcia-Perea A., et al. Activity of six quinolones against 226 recent clinical isolates of Streptococcus pyogenes with reduced susceptibility to ciprofloxacin. J Antimicrob Chemother 2002; 50:301-3.
-
9.
Drugeon H.D., Juvin M., Janus C. Antibacterial resistance among Streptococcus pyogenes isolated in Europe, Turkey, Middle East, Africa and Asia (eBASKETT 2). 44th ICAAC; Washington, USA; 2004. Abstract. C2-800.
-
10.
Bozdogan B., Appelbaum P.C., Kelly L.M., et al. Activity of telithromycin compared with seven other agents against 1039 Streptococcus pyogenes pediatric isolates from ten centers in central and Eastern Europe. Clin Microbiol Infect 2003; 9:741-5.
-
11.
Canton R., Loza E., Morosini M.I., Baquero F. Antimicrobial resistance amongst isolates of Streptococcus pyogenes and Staphylococcus aureus in the PROTEKT antimicrobial surveillance programme during 1999-2000. J Antimicrob Chemother 2002; 50 Suppl S1:9-24.
-
12.
Garcia-Rey C., Aguilar L., Baquero F., Casal J., Martin J.E. Pharmacoepidemiological analysis of provincial differences between consumption of macrolides and rates of erythromycin resistance among Streptococcus pyogenes isolates in Spain. J Clin Microbiol 2002; 40:2959-63.
-
13.
Bergman M., Huikko S., Pihlajamaki M., et al. Effect of macrolide consumption on erythromycin resistance in Streptococcus pyogenes in Finland in 1997-2001. Clin Infect Dis 2004; 38:1251-6.
-
14.
Fujita K., Murono K., Yoshikawa M., Murai T. Decline of erythromycin resistance of group A streptococci in Japan. Pediatr Infect Dis J 1994;13:1075-8.
-
15.
Kozlov R.S., Bogdanovitch T.M., Appelbaum P.C., et al. Antistreptococcal activity of telithromycin compared with seven other drugs in relation to macrolide resistance mechanisms in Russia. Antimicrob Agents Chemother 2002; 46:2963-8.
-
16.
Sauermann R., Garttringer R., Graninger W., Buxbaum A., Georgopoulos A. Phenotypes of macrolide resistance of group A streptococci isolated from outpatients in Bavaria and susceptibility to 16 antibiotics. J Antimicrob Chemother 2003; 51:53-7.